Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine ...

Vertex shares slipped in extended trading Wednesday after the company announced it had agreed to acquire Alpine Immune Sciences for $4.9 billion. The deal values each Alpine share at $65 ...

The rare disease specialist Vertex Pharmaceuticals(NASDAQ: VRTX) and the molecular cancer diagnostic stalwart Exact Sciences(NASDAQ: EXAS) are two of the best examples.

Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on ...

BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental therapy for type 1 diabetes, noting that the cell-based therapy achieved ...